Evidence map›Paper›PMID 37567447›Full record

ArticleAmerican journal of obstetrics & gynecology MFM2023

Neonatal outcomes and rationale for timing of birth in perinatal diabetes: a retrospective cohort study.

Sereen K Nashif, Renee M Mahr, Katelyn M Tessier, Elizabeth A Hoover, Oluwabukola Ajagbe-Akingbola, Emily Chiu, Janet I Andrews, Bethany A Sabol, William K Rogers, Sarah A Wernimont

Open access · bronzeAbstract read
In one paragraph

Article in American journal of obstetrics & gynecology MFM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Comparing perinatal outcomes in gestational and cystic-fibrosis related diabetes.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  4. Article
  5. Betamethasone latency period and neonatal hypoglycemia in term infants.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2025
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sereen K NashifDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont).
Renee M MahrDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont); Division of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN (Ms Mahr and Dr Wernimont).
Katelyn M TessierMasonic Cancer Center, Biostatistics Core, University of Minnesota, Minneapolis, MN (Ms Tessier).
Elizabeth A HooverDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont).
Oluwabukola Ajagbe-AkingbolaDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont).
Emily ChiuUniversity of Minnesota Medical School, University of Minnesota, Minneapolis, MN (Dr Chiu).
Janet I AndrewsDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont).
Bethany A SabolDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont).
William K RogersDepartment of Anesthesiology, University of Minnesota, Minneapolis, MN (Dr Rogers).
Sarah A WernimontDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN (Dr Nashif, Ms Mahr, Drs Hoover, Ajagbe-Akingbola, Andrews, Sabol, and Wernimont); Division of Molecular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN (Ms Mahr and Dr Wernimont). Electronic address: swernimo@umn.edu.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
REPRODUCTIVE SCIENTIST TRAINING PROGRAMK12HD000849 · NICHD · WASHINGTON UNIVERSITY · PI Danny J Schust · 1988 to 2026
$33.2M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598NICHD NIH HHS K12 HD000849
6 · The paper itself

Abstract

backgroundThe American College of Obstetricians and Gynecologists recommends delivery in the 39th week of pregnancy for patients with pregestational and medication-controlled gestational diabetes with consideration for earlier delivery among those with poor glucose control.

objectiveWe sought to evaluate the impact of birth before 39 weeks' gestation exclusively for diabetes-related indications on neonatal outcomes and clinician rationale for these recommendations. STUDY

designThis was a retrospective cohort study of all singleton, nonanomalous pregnancies complicated by diabetes. Patients were identified through an obstetrical database containing information of 90,185 births from 2011 to 2021. Patients who delivered in a given week of gestation exclusively for diabetes-related indications were compared with ongoing pregnancies. Recommended births for other obstetrical indications were excluded from the diabetes-related indications cohorts. The primary outcome was neonatal intensive care unit admission. Secondary outcomes included neonatal intensive care unit length of stay, stillbirth, neonatal death, hypoglycemia, respiratory distress syndrome, and shoulder dystocia. For all births before 39 weeks' gestation, the electronic medical records were reviewed to confirm the rationale for the intervention for a diabetes-indicated condition.

resultsFrom the 90,185 recorded births that occurred in 2011 to 2021, 4750 patients with diabetes were identified. Of those, 30.5% (n=1449) had a recommended birth for a diabetes-related indications with 2.2% of those (n=32) occurring at 36 weeks' gestation, 7.9% (n=114) at 37 weeks' gestation, 9.7% (n=141) at 38 weeks' gestation, and 63.0% (n=913) at 39 weeks' gestation. Births that occurred at 36 and 37 weeks' gestation exclusively for diabetes-related indications had higher rates of neonatal intensive care unit admission than the respective ongoing pregnancies (62.5% vs 8.7%; P<.001 and 25.4% vs 7.2%; P<.001). There was no difference in neonatal intensive care unit admission for births at 38 or 39 weeks' gestation when compared with ongoing pregnancy. For neonates born at 36 and 37 weeks' gestation in comparison with ongoing pregnancies, the median neonatal intensive care unit length of stay was 11.0 vs 2.8 days, (P<.001) and 4.4 vs 2.6 days (P=.026), respectively. There were significantly increased rates of neonatal hypoglycemia and respiratory distress syndrome among births that occurred at 36, 37, and 38 weeks' gestation when compared with ongoing pregnancies. There were no differences in the rate of stillbirth in this cohort. Primary factors cited for early birth were poor glycemic control (71.4%), recommendation by a maternal-fetal medicine specialist (38.7%), and suspected fetal macrosomia (27.9%). Overall, 46.7%, 32.8%, and 20.6% of patients had 1, 2, or ≥3 indications, respectively, listed as rationale for early birth. Overall, few objective measures were used to recommend birth before 39 weeks' gestation owing to diabetes.

conclusionIn pregnancies complicated by diabetes, early birth exclusively for diabetes-related indications was associated with increased neonatal intensive care unit admission and length of stay and with neonatal morbidity. Little objective data are documented by clinicians to support their recommendations for early birth associated with diabetes. Additional clinical guidelines are needed to define suboptimal glucose control necessitating birth before 39 weeks' gestation.

Indexed as

Diabetes, GestationalHypoglycemiaRespiratory Distress SyndromeBlood GlucoseFemaleHumansInfant, NewbornPregnancyRetrospective StudiesStillbirthBlood Glucosediabetesgestational diabetesglucose controlneonatal outcomespregestational diabetespregnancytiming of birthtiming of deliverytype 1 diabetestype 2 diabetes

Identifiers

PMID37567447
PMCPMC10592060
OpenAlexW4385708626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.